Other substances

GSK-256066

A quinoline-3-carboxamide investigational drug.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

GSK-256066 is a substance investigated for the treatment of respiratory tract inflammatory conditions (DrugBank).

GSK-256066 on PubChem

Synonyms

6-[[3-[(Dimethylamino)carbonyl]phenyl]sulfonyl]-4-[(3-methoxyphenyl)amino]-8-methyl-3-quinolinecarboxamide

 

Structure image - GSK-256066

CC1=CC(=CC2=C(C(=CN=C12)C(=O)N)NC3=CC(=CC=C3)OC)S(=O)(=O)C4=CC=CC(=C4)C(=O)N(C)C

Supporting references

Link Tested on Impact factor Notes Publication date
Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
3CLpro Small molecule Enzyme assay In vitro In silico 		in silico; in vitro enzyme assay 4.00

Displayed inhibitory activity against SARS-CoV-2 3C-like protease in vitro (over 30% at 50 μM). More accurate measurements are needed, however.

 Nov/30/2020
Export (.csv)